SynthesisBMC gastroenterology2026
The effect of TIPS on the development of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis.
Synthesis in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLiver cirrhosis is a leading cause of global liver-related morbidity and mortality, with hepatocellular carcinoma (HCC) being the most common and fatal complication. Transjugular intrahepatic portosystemic shunt (TIPS) is a minimally invasive treatment for ascites and gastrointestinal bleeding in patients with cirrhosis. Whether transjugular intrahepatic portalsystemic shunt (TIPS) increases the incidence of hepatocellular carcinoma (HCC) in patients with cirrhosis remains controversial. This study aimed to explore the association between TIPS and the development of HCC.
methodsWe systematically researched PubMed, Embase, Cochrane Library, and Web of Science databases from their inception until March 7, 2023, to identify eligible studies. The incidence of HCC was extracted and analyzed using a random-effects in RevMan. The primary outcome was the cumulative incidence of HCC, and secondary outcomes included subgroup HCC risk by etiology, stent type, follow-up duration, and overall survival. This study was registered with PROSPERO (CRD42023442262).
resultsTen studies comprising 2753 patients were included. Among the 1070 patients who received TIPS, 11.31% (121/1070 ) developed HCC, compared with 8.85% (149/1683) developed HCC (8.85%) in 1683 non-TIPS patients. TIPS did not increase the incidence of HCC [OR = 1.16, 95%CI (0.76,1.77), P = 0.51, I²=50%]. We then performed the analysis according to etiology and stent type. In studies primarily focused on alcoholic liver disease, TIPS did not increase the incidence of HCC [OR = 1.07 95% CI (0.61,1.88), P = 0.82, I²=67%]. Comparable results were observed in studies predominantly using bare stents [OR = 1.52, 95% CI (0.98,2.37), P = 0.06, I²=12%]. Furthermore, TIPS did not increase the cumulative incidence of cancer in 1 year [OR = 0.73 95%CI (0.20,2.69), P = 0.63, I²=74%] and 5 years [OR = 0.99 95% CI (0.52,1.87), P = 0.96], nor did it affect the survival rate [OR = 1.22,95% CI (0.65,2.32), P = 0.53, I²=44%].
conclusionsTIPS is not associated with an increased risk of HCC development in cirrhosis patients. Clinicians can safely select TIPS as a treatment option for cirrhotic patients with portal hypertension, without excessive concern about an elevated risk of HCC associated with the procedure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.